Sign in

CIK 0002124080 · <br>Emerging growth company

Aspen Neuroscience, Inc.

Sign in to watch
Ticker
ASPE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
other
EIN
831312969
Phone
858.263.1222
Business address
10835 ROAD TO THE CURE, SUITE 100, SAN DIEGO, CA, 92121
Open-market buys, last 90 days
$67,999,995
in 4 filings
Open-market sales, last 90 days
$0
in 0 filings

Net +$67,999,995. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. ARCH Venture Fund X, L.P. +$20.0M 10% owner 1 filing
  2. ARCH Venture Partners XIV, L.P. +$18.0M 10% owner 1 filing
  3. ORBIMED ADVISORS LLC +$15.0M Director 1 filing
  4. Thompson Peter A. +$15.0M Director 1 filing
Date Insider Transaction Shares Price Value Owned after
2026-11-05 Hasnain Faheem Executive Chair Grant or award +321,672 348,330
2026-11-02 Thompson Peter A. Director Conversion +196,541 196,541
2026-11-02 Thompson Peter A. Director Conversion +642,745 839,286
2026-11-02 Thompson Peter A. Director Conversion +616,984 1,456,270
2026-11-02 Thompson Peter A. Director Conversion +625,743 2,082,013
2026-11-02 Thompson Peter A. Director Conversion +507,119 2,589,132
2026-11-02 Thompson Peter A. Director Purchase +1,000,000 $15.00 $15.0M 3,589,132
2026-11-02 Thompson Peter A. Director Conversion · Series Seed-2 Convertible Preferred Stock −196,541 0
2026-11-02 Thompson Peter A. Director Conversion · Series A-1 Convertible Preferred Stock −642,745 0
2026-11-02 Thompson Peter A. Director Conversion · Series A-2 Convertible Preferred Stock −616,984 0
2026-11-02 Thompson Peter A. Director Conversion · Series B Convertible Preferred Stock −625,743 0
2026-11-02 Thompson Peter A. Director Conversion · Series C Convertible Preferred Stock −507,119 0
2026-11-02 ORBIMED ADVISORS LLC Director Conversion +196,541 196,541
2026-11-02 ORBIMED ADVISORS LLC Director Conversion +642,745 839,286
2026-11-02 ORBIMED ADVISORS LLC Director Conversion +616,984 1,456,270
2026-11-02 ORBIMED ADVISORS LLC Director Conversion +625,743 2,082,013
2026-11-02 ORBIMED ADVISORS LLC Director Conversion +507,119 2,589,132
2026-11-02 ORBIMED ADVISORS LLC Director Purchase +1,000,000 $15.00 $15.0M 3,589,132
2026-11-02 ORBIMED ADVISORS LLC Director Conversion · Series Seed-2 Convertible Preferred Stock −196,541 0
2026-11-02 ORBIMED ADVISORS LLC Director Conversion · Series A-1 Convertible Preferred Stock −642,745 0

Page 1 of 3 · 55 trades